It was a busy week in the innovation arena, with several companies announcing the use of an expedited pathway.
Keeping Track: An RMAT, Two QIDPs, And Some Bad News Too
The latest drug development news and highlights from our FDA Performance Tracker.
The latest drug development news and highlights from our FDA Performance Tracker.
It was a busy week in the innovation arena, with several companies announcing the use of an expedited pathway.